American Association for Cancer Research’s Post

Exciting news! Our Business Development team is in Charlotte, North Carolina this week end to attend the AACR special conference on bladder cancer. If you're attending as well, be sure to stop by our booth to learn about how our cutting-edge #MIBC and #NMIBC models for preclinical oncology drug development. See you there! Discover more https://hubs.ly/Q02xFVXb0 #AACR2024 #BladderCancer #OncologyResearch #PreclinicalDrugDevelopment.

The first clinical data for casdatifan, our HIF-2a inhibitor for the treatment of #kidneycancer, will be presented in an oral plenary session at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Read more about this news and the posters we’ll be presenting: https://bit.ly/3YeEM5Y #ENASymp24

Great to see Alligator Bioscience AB's #mitazalimab pancreatic cancer data from the Optimize-1 trial feature in the Labiotech.eu #ASCO 2024 summary! Here's the link to the full article: https://lnkd.in/df_D_Cri

Find out more in the September issue of Cancer Discovery! AACR Journals

The Pfizer, Pfizer Boulder Research Unit, and academic collaborators' clinical and translational work on PF-07799933 (ARRY-440) is out in the September issue of Cancer Discovery. A next-generation, brain-penetrant, pan-mutant BRAF-selective inhibitor, together with innovative and accelerated phase 1 clinical development with demonstrated efficacy in treatment-refractory cancer patients. https://lnkd.in/gmQKJkNz

This week’s new issue of #ScienceSignaling is out now! A preclinical study offers insights into the origins of resistance to MAPK inhibitors in cancer cells, our new Editors’ Choice piece highlights research on the role of lactate in cancer-associated cachexia, and more. https://scim.ag/6X4

🔊 Latest news!   🧬Controlling MYC’s hyperactivity with a peptide compound University of California, Riverside (UCR) researchers have discovered that a novel peptide can suppress MYC by binding directly to it with sub-micro-molar affinity, advancing cancer drug development. Click on the link in the comments to read more 👇   #peptide #cancer #drugdevelopment  

Article No. 133 Title: Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC). Journal: Bioorganic & medicinal chemistry Impact Factor: 3.3 DOI: https://lnkd.in/gRnnwe-S

Download this new poster for an insight into glycan-protein interactions! Learn how heparan sulfate (HS) and chondroitin sulfate (CS) influence everything from cell migration to cancer metastasis. Discover how Glycan Therapeutics can provide you with the tools needed to delve into carbohydrate-protein interactions! >>> https://hubs.ly/Q02Hpkn60

Download this new poster for an insight into glycan-protein interactions! Learn how heparan sulfate (HS) and chondroitin sulfate (CS) influence everything from cell migration to cancer metastasis. Discover how Glycan Therapeutics can provide you with the tools needed to delve into carbohydrate-protein interactions! >>> https://hubs.ly/Q02JbQ_H0